tetano
Editor, Senior Moderator
Nihon Rinsho. 2012 Apr;70(4):568-73.
[Anti-influenza virus agent].
[Article in Japanese]
Nakamura S, Kohno S.
Source
Department of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Science.
Abstract
The necessity of newly anti-influenza agents is increasing rapidly after the prevalence of pandemic influenza A (H1N1) 2009. In addition to the existing anti-influenza drugs, novel neuraminidase inhibitors such as peramivir (a first intravenous anti-influenza agent) and laninamivir (long acting inhaled anti-influenza agent) can be available. Moreover favipiravir, which shows a novel anti-influenza mechanism acting as RNA polymerase inhibitor, has been developing. These drugs are expected to improve the prognosis of severe cases caused by not only seasonal influenza but pandemic influenza A (H1N1) 2009 virus and H5N1 avian influenza, and also treat oseltamivir-resistant influenza effectively.
PMID:
22568136
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/22568136
[Anti-influenza virus agent].
[Article in Japanese]
Nakamura S, Kohno S.
Source
Department of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Science.
Abstract
The necessity of newly anti-influenza agents is increasing rapidly after the prevalence of pandemic influenza A (H1N1) 2009. In addition to the existing anti-influenza drugs, novel neuraminidase inhibitors such as peramivir (a first intravenous anti-influenza agent) and laninamivir (long acting inhaled anti-influenza agent) can be available. Moreover favipiravir, which shows a novel anti-influenza mechanism acting as RNA polymerase inhibitor, has been developing. These drugs are expected to improve the prognosis of severe cases caused by not only seasonal influenza but pandemic influenza A (H1N1) 2009 virus and H5N1 avian influenza, and also treat oseltamivir-resistant influenza effectively.
PMID:
22568136
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/22568136